Nirsevimab is recommended for preventing RSV lower respiratory tract infection in infants younger than one year in their ...

Respiratory syncytial virus infection in adults aged 45 years or older is significantly associated with a higher 1-year risk ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...

According to the NHS, people infected with RSV will typically show symptoms within the first few days of infection. This can ...

Recovering from respiratory syncytial virus often doesn't end when it's time to leave the hospital, even for younger adults.

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

An infection with respiratory syncytial virus (RSV) typically affects infants much harder than adults. While adults usually ...

For the first study, published yesterday in JAMA Network Open, Danish researchers used national registry data to assess rates ...